The Receptors That Decide When GLP-1 Comes Out

The question this library had not asked

There is a large body of work on what GLP-1 does once it is in circulation and comparatively little written for general readers on what causes it to be there. That is the wrong way round for understanding the class, because almost every claim about raising GLP-1 by dietary means is a claim about this machinery, and the machinery is specific enough to check those claims against.

Glucose is not sensed the way most explanations say

The intuitive account is that the cell takes up glucose, metabolises it, and the resulting rise in ATP triggers secretion - the mechanism that operates in the pancreatic beta cell. That is not the predominant route here. Reimann and Gribble describe a predominant role for electrogenic glucose uptake through sodium-coupled glucose transporter 1. SGLT1 carries glucose together with sodium ions, and it is the movement of that positive charge across the membrane that depolarises the cell and opens voltage-gated calcium channels. The signal is the current, not the calorie. That distinction has a practical consequence: a substance that is transported by SGLT1 but poorly metabolised can still trigger secretion, and a sugar that is metabolised but not carried by SGLT1 may not.

Fat is sensed by receptors, not by absorption

Long-chain fatty acids are detected by two G-protein-coupled receptors on the cell surface, FFAR1 - also called GPR40 - and FFAR4, also called GPR120. These are receptors in the ordinary sense: the fatty acid binds the outside of the protein and the protein signals inward. GPR119 responds to lipid-derived molecules including monoacylglycerols and the endogenous lipid oleoylethanolamide, and Reimann and Gribble note it has a clearly documented role in GLP-1 secretion specifically. Each of these has been pursued as a drug target on the reasoning that an agonist would raise endogenous GLP-1; none has produced a licensed weight-management medicine, which is itself informative.

The bacterial channel

FFAR2 and FFAR3 respond to short-chain fatty acids - acetate, propionate and butyrate - which are not dietary components in any direct sense. They are produced by bacterial fermentation of material the human small intestine cannot digest, principally in the colon. This is the mechanistic link between fermentable fibre and GLP-1 secretion, and it is a genuinely indirect one: the fibre is not detected, its bacterial breakdown products are. It also explains why the effect depends on which bacteria are present, which is why the same intake produces different results in different people.

Two cells, nearly the same sensors

GIP comes from K cells and GLP-1 from L cells, and in labelled models more than 80% of cells produce only one of the two hormones. Transcriptomic analysis shows a close relationship between small intestinal K and L cells, and the glucose-sensing mechanism appears similar in both, with SGLT1 predominant in each. Both express FFAR1 and FFAR4. Where they differ is in other lipid-sensing receptors: GPR119 and FFAR2/3 have documented roles in GLP-1 secretion, while agonists for the endocannabinoid receptor type 1 selectively inhibit GIP secretion. The authors' conclusion is that these subtle differences might be exploited to modulate one incretin rather than the other - which is a striking idea given how much of this field concerns whether GIP agonism or antagonism is preferable alongside GLP-1.

What this does and does not license

It licenses precise statements about which stimuli engage which sensor. It does not license the leap that is usually made next - that engaging these sensors produces anything resembling the effect of a GLP-1 receptor agonist. That question is quantitative rather than mechanistic, and it is addressed separately. Nothing in this article concerns any product, and nothing supplied on this site acts on any of the receptors described here.

Quick reference